Published in:
01-06-2013 | CIRSE Standards of Practice Guidelines
Standards of Practice in Transarterial Radioembolization
Authors:
Andreas H. Mahnken, Carlo Spreafico, Geert Maleux, Thomas Helmberger, Tobias F. Jakobs
Published in:
CardioVascular and Interventional Radiology
|
Issue 3/2013
Login to get access
Excerpt
Primary cancer to the liver is the second most frequent cause of cancer death worldwide. There are 750,000 new cases of liver cancer worldwide [
1], and metastatic liver disease is the most common cause of cancer death. Only about 25 % of patients with primary or secondary liver cancer are eligible for surgery, with a roughly 50 % 5-year overall survival in metastatic colorectal cancer (CRC) and little more than 20 months’ median overall survival with systemic chemotherapy alone [
2]. Thus, interventional techniques evolved as a first-line treatment in primary liver tumors and are increasingly used in metastatic liver disease. Radiation-based approaches are appealing because they are known to be cytocidal in sufficient doses and they are independent from chemical or other energy-based treatment techniques. Although delivery of >70 Gy is thought to be needed to achieve solid tumor destruction [
3], the tolerance of normal liver tissue is approximately 30 Gy [
4]. These conditions resulted in the idea of selective transarterial radiation delivery and triggered the development of various transarterial radiation-based therapies, with
90Y microspheres being the current mainstay of radioembolization (RE). …